Effects of melatonin on oxidative stress, and resistance to bacterial, parasitic, and viral infections: A review

Acta Tropica

Volumn 137, Issue , 2014, Pages 31-38

  Vielma, José Ramón ^a   Bonilla, Ernesto ^a,b   Chacín Bonilla, Leonor ^b   Mora, Marylú ^a   Medina Leendertz, Shirley ^a   Bravo, Yanauri ^a  

^a INSTITUTO VENEZOLANO DE INVESTIGACIONES CIENTÍFICAS   (Venezuela)

^b UNIVERSIDAD DEL ZULIA   (Venezuela)

Author keywords

Bacterial infections; Inflammation; Melatonin; Oxidative stress; Parasitic infections; Viral infections

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN M; INTERLEUKIN 1BETA; INTERLEUKIN 2; MELATONIN; NITRIC OXIDE; PHOSPHOLIPASE C; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; ANTIOXIDANT; IMMUNOLOGIC FACTOR;

ANTIOXIDANT; BACTERIAL DISEASE; DISEASE RESISTANCE; HORMONE; PARASITIC DISEASE; VIRAL DISEASE;

ANTIBODY TITER; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTIOXIDANT ACTIVITY; BACTERIAL INFECTION; CLOSTRIDIUM PERFRINGENS; CYTOKINE PRODUCTION; ENTAMOEBA HISTOLYTICA; ENZYME ACTIVATION; HELICOBACTER PYLORI; HORMONE ACTION; HUMAN; IMMUNIZATION; IMMUNOMODULATION; KLEBSIELLA PNEUMONIAE; LIPID PEROXIDATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OPISTHORCHIS VIVERRINI; OXIDATIVE STRESS; PARASITE LOAD; PARASITOSIS; PLASMODIUM CHABAUDI; PLASMODIUM FALCIPARUM; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; TOXOPLASMA GONDII; TROPHOZOITE; TRYPANOSOMA CRUZI; VENEZUELAN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS; VIRUS INFECTION; BACTERIAL INFECTIONS; DISEASE RESISTANCE; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; PARASITIC DISEASES; VIRUS DISEASES;

ANTIOXIDANTS; BACTERIAL INFECTIONS; DISEASE RESISTANCE; HUMANS; IMMUNOLOGIC FACTORS; MELATONIN; OXIDATIVE STRESS; PARASITIC DISEASES; VIRUS DISEASES;

EID: 84901362118     PISSN: 0001706X     EISSN: 18736254     Source Type: Journal    
DOI: 10.1016/j.actatropica.2014.04.021     Document Type: Review

References (117)

1. Ahmadiasl N., Banaei S., Alihemmati A., Baradaran B., Azimian E. The anti-inflammatory effect of erythropoietin and melatonin on renal ischemia reperfusion injury in male rats. Adv. Pharm. Bull. 2014, 4:49-54.
2. 2+ release from intracellular stores in the malaria parasite Plasmodium falciparum within infected red blood cells. J. Biol. Chem. 2011, 286:5905-5912.
3. Arendt J. Melatonin: characteristics, concerns, and prospects. J. Biol. Rhythm. 2005, 20:291-303.
4. Arias J., Meleán E., Valero N., Ponds H., Chacín-Bonilla L., Larreal Y., Bonilla E. Efecto de la melatonina en la proliferación linfocitaria y la producción de interleucina 2 (IL-2) e interleucina 1 beta (IL-1β) en esplenocitos de ratones. Invest. Clin. 2003, 44:41-50.
5. Arzt E., Fernández-Casteló S., Finocchiaro L., Criscuolo M.E., Díaz A., Finkielman S., Nahmod V.E. Immunomodulation by indoleamines: serotonin and melatonin action on DNA and interferon-gamma synthesis by human peripheral blood mononuclear cells. J. Clin. Immunol. 1988, 8:513-520.
6. Avunduk A.M., Avunduk M.C., Baltaci A.K., Mogulkoc R. Effect of melatonin and zinc on the immune response in experimental Toxoplasma retinochoroiditis. Ophtalmologica 2007, 221:421-425.
7. Baltaci A.K., Bediz C.S., Mogulkoc R., Kurtoglu E., Pekel A. Effect of zinc and melatonin supplementation on cellular immunity in rats with toxoplasmosis. Biol. Trace Elem. Res. 2003, 96:237-245.
8. Baltaci A.K., Mogulkoc R., Turkoz Y., Bediz C.S., Ozugurlu F. The effect of pinealectomy and zinc deficiency on nitric oxide levels in rats with induced Toxoplasma gondii infection. Swiss Med. Wkly. 2004, 134:359-363.
9. Baltaci A.K., Mogulkoc R., Bediz C.S., Pekel A. Effects of zinc deficiency and pinealectomy on cellular immunity in rats infected with Toxoplasma gondii. Biol Trace Elem. Res. 2005, 104:47-56.
10. Ben-Nathan D., Mestroni G.J.M., Lustig S., Conti A. Protective effects of melatonin in mice infected with encephalitis virus. Arch. Virol. 1995, 140:223-230.
11. Beraldo F.H., Almeida F.M., da Silva A.M., García C.R.S. Cyclic AMP and calcium interplay as second messengers in melatonin-dependent regulation of Plasmodium falciparum cell cycle. J. Cell Biol. 2005, 170:551-557.
12. Bonilla E., Prasad A.L.N., Estévez J., Hernández H., Arrieta A. Changes in serum and striatal free amino acids after Venezuelan equine encephalomyelitis virus. Exp. Neurol. 1988, 99:647-654.
13. Bonilla E., Valero N., Ponds H., Chacín-Bonilla L. Melatonin protects mice infected with Venezuelan equine encephalomyelitis virus. Cell. Mol. Life Sci. 1997, 53:430-434.
14. Bonilla E., Rondón C., Valero N., Ponds H., Chacín-Bonilla L., García Tamayo J., Rodriguez Z., Medina-Leendertz S., Añez F. Melatonin prolongs survival of immunodepressed mice infected with the Venezuelan equine encephalomyelitis virus. Trans. R. Soc. Trop. Med. Hyg. 2001, 95:207-210.
15. Bonilla E., Valero N., Chacín-Bonilla L., Ponds H., Larreal Y., Medina-Leendertz S., Espina L.M. Melatonin increases interleukin-1 beta and decreases tumor necrosis factor alpha in the brain of mice infected with the Venezuelan equine encephalomyelitis virus. Neurochem. Res. 2003, 28:681-686.
16. Bonilla E., Valero N., Chacín-Bonilla L., Medina-Leendertz S. Melatonin and viral infections. J. Pineal Res. 2004, 36:73-79.
17. Bowen G.S., Calisher C.H. Virological and serological studies of Venezuelan equine encephalomyelitis in humans. J. Clin. Microbiol. 1976, 4:22-27.
18. Brazao V., Del Vecchio Filipin M., Santello F.H., Caetano L.C., Abrahao A.A., Toldo M.P., do Prado J.C. Melatonin and zinc treatment: distinctive modulation of cytokine production in chronic experimental Trypanosoma cruzi infection. Cytokine 2011, 56:627-632.
19. Calisher C.H., Karabatsos N. Arbovirus serogroups: definition and geographic distribution. The Arboviruses: Epidemiologic and Ecology 1988, 19-57. CRC Press, Boca Raton. T.P. Monath (Ed.).
20. Cardinali D.P., Alvarez C.B. Melatonin in Chagas' disease. Possible therapeutic value. Medicina (B. Aires) 2011, 71:477-483.
21. Carrillo-Vico A., Guerrero J.M., Lardone P.J., Reiter R.J. A review of the multiple actions of melatonin on the immune system. Endocrine 2005, 27:189-200.
22. Carrillo-Vico A., Lardone P.J., Alvarez-Sánchez N., Rodríguez-Rodríguez A., Guerrero J.M. Melatonin: buffering the immune system. Int. J. Mol. Sci. 2013, 14:8638-8683.
23. Chacín-Bonilla L., Sánchez Y., Monsalve F., Estévez J. Seroepidemiology of toxoplasmosis in Amerindians from Western Venezuela. Am. J. Trop. Med. Hyg. 2001, 65:131-135.
24. Chacín-Bonilla L., Sánchez Y., Estévez J., Larreal Y., Molero E. Prevalence of human toxoplasmosis in San Carlos Island, Venezuela. Interciencia 2003, 28:457-462.
25. Chacín-Bonilla L. Amibiasis Implicaciones del reconocimiento de Entamoeba dispar y de la identificación de Entamoeba moshkovskii en humanos. Invest. Clín. 2010, 51:239-256.
26. Chacín-Bonilla L. Amebiasis: aspectos clínicos, terapéuticos y de diagnóstico de la infección. Rev. Med. Chile 2013, 141:609-615.
27. Charles P., Walter E., Margolis F., Johnston R.E. Mechanism of neuroinvasion of Venezuelan equine encephalitis virus in the mouse. Virology 1995, 208:662-671.
28. Chojnacki C., Poplawski T., Blasiak J., Chojnacki J., Reiter R.J., Klupinska G. Expression of melatonin synthesizing enzymes in Helicobacter pylori infected gastric mucosa. Biomed. Res. Int. 2013, 2013:845032.
29. Crespo E., Macías M., Pozo D., Escames G., Martín M., Vives F., Guerrero J.M., Acuña-Castroviejo D. Melatonin inhibits expressions of the inducible NO synthase II in liver and lung and prevents endotoxemia in lipopolysaccharide-induced multiple organ dysfunction syndrome in rats. FASEB J. 1999, 13:1537-1546.
30. Dubocovich M.L., Delagrange P., Krause D.N., Sugden D., Cardinali D.P., Olcese J. International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors. Pharmacol. Rev. 2010, 52:343-380.
31. Emerit I., Filipe P., Freitas J., Vassy J. Protective effect of superoxide dismutase against hair graying in a mouse model. Photochem. Photobiol. 2004, 80:579-582.
32. Fang C.T., Chen Y.C., Chang S.C., Sau W.Y., Luh K.T. Klepsiella pneumoniae meningitis: timing of antimicrobial therapy and prognosis. QJM 2000, 93:45-53.
33. Franca Botelho A.C., Franca J.L., Oliveira F.M.S., Franca E.L., Honorio-Franca A.C., Caliari M.V., Gomes M.A. Melatonin reduces the severity of experimental amoebiasis. Parasit. Vectors 2011, 4. 10.1186/1756-3305-4-62.
34. Frank L. Oxygen toxicity in eukaryotes. Superoxide dismutase, pathological states 1985, vol. 3:1-43. CRC Press, Boca Raton.
35. Fredriksson R., Lagerström M.C., Lundin L.G., Schiöth H.B. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol. Pharmacol. 2003, 63:1256-1272.
36. Galano A., Tan D.X., Reiter R.J. Melatonin as a natural ally against oxidative stress: a physicochemical examination. J. Pineal Res. 2011, 51:1-16.
37. Galano A., Tan D.X., Reiter R.J. On the free radical scavenging activities of melatonin's metabolites, AFMK and AMK. J. Pineal Res. 2013, 54:245-257.
38. Gazarini M.L., Beraldo F.H., Almeida F.M., Bootman M., Da Silva A.M., Garcia C.R. Melatonin triggers PKA activation in the rodent malaria parasite Plasmodium chabaudi. J. Pineal Res. 2011, 50:64-70.
39. Guha M., Maity P., Choubey V., Mitra K., Reiter R.J., Bandyopadhyay U. Melatonin inhibits free radical-mediated mitochondrial-dependent hepatocyte apoptosis and liver damage induced during malarial infection. J. Pineal Res. 2007, 43:372-381.
40. Hardeland R., Tan D.X., Reiter R.J. Kynuramines metabolites of melatonin and other indoles: the resurrection of an almost forgotten class of biogenic amines. J. Pineal Res. 2009, 47:109-126.
41. Harman D. Aging: a theory based on free radical and radiation chemistry. J. Gerontol. 1956, 11:298-300.
42. Hotta C.T., Markus R.P., García C.R.S. Melatonin and N-acetyl-serotonin cross the red blood cell membrane and evoke calcium mobilization in malarial parasites. Braz. J. Med. Biol. Res. 2003, 36:1583-1587.
43. Huang S.H., Cao X.J., Liu W., Shi X.Y., Wei W. Inhibitory effect of melatonin on lung oxidative stress induced by respiratory syncytial virus infection in mice. J. Pineal Res. 2010, 48:109-116.
44. Jung-Hynes B., Reiter R.J., Ahmad N. Sirtuins, melatonin and circadian rhythms: building a bridge between aging and cancer. J. Pineal Res. 2010, 48:9-19.
45. Kuehn C.C., Rodrigues Oliveira L.G., Santos C.D., Ferreira D.S., Alonso Toldo M.P., de Albuquerque S., do Prado J.C. Melatonin and dehydroepiandrosterone combination: does this treatment exert a synergistic effect during experimental Trypanosoma cruzi. J. Pineal Res. 2009, 47:253-259.
46. Laothong U., Pinlaor P., Boonsin P., Pairoikul C., Priprem A., Johns N.P., Charoensuk L., Intuyod K., Pinlaor S. Melatonin inhibits cholangiocarcinoma and reduces liver injury in Opisthorchis viverrini-infected and N-nitrosodimethylamine-treated hamsters. J. Pineal Res. 2013, 55:257-266.
47. Lerner A.B., Case J.D., Heinzelman R.V. Structure of melatonin. J. Am. Chem. Soc. 1959, 81:6084-6085.
48. Li D.Y., Smith D.G., Hardeland R., Yang M.Y., Xu H.L., Zhang L., Yin H.D., Zhu Q. Melatonin receptor genes in vertebrates. Int. J. Mol. Sci. 2013, 14:11208-11223.
49. Lim H.D., Kim Y.S., Ko S.H., Yoon I.J., Cho S.G., Chun Y.H., Choi B.J., Kim E.C. Cytoprotective and anti-inflammatory effects of melatonin in hydrogen peroxide-stimulated CHON-001 human chondrocyte cell line and rabbit model of osteoarthritis via the SIRT1 pathway. J. Pineal Res. 2012, 53:225-237.
50. Lima W.R., Moraes M., Alves E., Azevedo M.F., Passos D.O., Garcia C.R. The PfNF-YB transcription factor is a downstream target of melatonin and cAMP signaling in the human malaria parasite Plasmodium falciparum. J. Pineal Res. 2013, 54:145-153.
51. Lima W.R., Holder A.A., Garcia C.R. Melatonin signaling and its modulation of PfNF-YB transcription factor expression in Plasmodium falciparum. Int. J. Mol. Sci. 2013, 14:13704-13718.
52. Lissoni P., Barni S., Tancini G., Rovelli F., Ardizzola A., Conti A., Maestroni G.J. A study of the mechanism involved in the immunostimulatory action of the pineal hormone in cancer patients. Oncology 1993, 50:399-402.
53. 2-formyl-5-methoxykynuramine and 6-hydroxymelatonin reduce oxidative DNA damage induced by Fenton reagents. J. Pineal Res. 2003, 34:178-184.
54. Lyssenko V., Nagorny C.L.F., Erdos M.R., Wierup N., Jonsson A., Spégel P., Bugliani M., Saxena R., Fex M., Pulizzi N., Isomaa B., Tuomi T., Nilson P., Kuusisto J., Tuomilehto J., Boehnke M., Altshuler D., Sundler F., Eriksson J.G., Jackson A.U., Laakso M., Marchetti P., Watanabe R.M., Mulder H., Groop L. Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion. Nat. Genet. 2009, 41:82-88.
55. Macias M., Rodriguez-Cabezas M.N., Reiter R.J., Osuna A., Acuña-Castroviejo D. Presence and effects of melatonin in Tripanosoma cruzi. J. Pineal Res. 1999, 27:86-94.
56. Maestroni G.J.M., Conti A., Pierpaoli W. Pineal melatonin its fundamental immuno-regulatory role in aging and cáncer. Ann. N. Y. Acad. Sci. 1988, 521:140-148.
57. Mahal H.S., Sharma H.S., Mukerjee T. Antioxidant properties of melatonin: a pulse radiolysis study. Free Radic. Biol. Med. 1999, 26:557-565.
58. Martin-Cano F.E., Camello-Almaraz C., Acuña-Castroviejo D., Pozo M.J., Camello P.J. Age-related changes in mitochondrial of mouse colonic smooth muscle: beneficial effects of melatonin. J. Pineal Res. 2013, 10.1111/jpi.12109.
59. McNamara P.S., Smyth R.L. The pathogenesis of respiratory syncytial virus disease in childhood. Br. Med. Bull. 2002, 61:13-28.
60. Medina S., Valero-Fuenmayor N., Chacín-Bonilla L., Añez F., Giraldoth D., Arias J., Espina G., Achong A.Y., Bonilla E. Exposure to 2500lux increases serum melatonin in Venezuelan equine encephalomyelitis. Neurochem. Res. 1999, 24:775-778.
61. Medina-Leendertz S., Valero N., Chacín-Bonilla L., Añez F., Giraldoth D., Arias J., Espina G., Díaz S., Bonilla E. High intensity light increases olfactory bulb melatonin in Venezuelan equine encephalomyelitis virus infection. Neurochem. Res. 2001, 26:231-234.
62. Negrette A., Mosquera J. Epidemia de encefalitis de 1959 en Maracaibo (San Francisco) estado Zulia, Venezuela. Manifestaciones clínicas y terapéutica antibiótica. Invest. Clin. 1974, 15:11-44.
63. Negrette B., Bonilla E., Valero N., Ponds H., García Tamayo J., Chacín-Bonilla L., Medina-Leendertz S., Añez F. Melatonin treatment enhances the efficiency of miceimmunization with Venezuelan equine encephalomyelitis virus TC-83. Neurochem. Res. 2001, 26:765-768.
64. Okatani Y., Okamoto K., Hayashi K., Wakatsuki A., Sagara Y. Maternal-fetal transfer of melatonin in human pregnancy near term. J. Pineal Res. 1998, 25:129-134.
65. Oliveira L.G., Kuehn C.C., Santos C.D., Toldo M.P., do Prado J.C. Enhanced protection by melatonin and meloxicam combination in experimental infection with Tripanosoma cruzi. Parasite Immunol. 2010, 32:245-251.
66. Oliveira L.G., Kuehn C.C., dos Santos C.D., Miranda M.A., da Costa C.M., Mendonca V.J., do Prado J.C. Protective actions of melatonin against heart damage during chronic Chagas disease. Acta. Trop. 2013, 128:652-658.
67. Osadchuk M.A., Sibriaev A.A., Kireeva N.V., Kvetnoǐ I.M. The influence of melatonin included in the combined treatment of antichelicabacterial therapy on immunohistochemical characteristics of gastric epitheliocytes from patients with duodenal ulcer. Klin. Med. 2012, 90:48-52.
68. Ozkan E., Yaman H., Cakir E., Deniz O., Oztosun M., Gumus S., Akqul E.O., Agilli M., Cayci T., Kurt Y.G., Aydin I., Arslan Y., IIhan N., IIhan N., Erbil M.K. Plasma melatonin and urinary 6-hydroxymelatonin levels in patients with pulmonary tuberculosis. Inflammation 2012, 35:1429-1434.
69. Pala D., Lodola A., Bedini A., Spadoni G., Rivara S. Homology models of melatonin receptors: challenges and recent advances. Int. J. Mol. Sci. 2013, 14:8093-8121.
70. Pandi-Perumal S.R., Srinivasan V., Maestroni G.J.M., Cardinali D.P., Poeggeler B., Hardeland R. Melatonin: nature's most versatile biological signal?. FEBS J. 2006, 273:2813-2838.
71. Pandi-Perumal S.R., Trakht I., Srinivasan V., Spence D.W., Maestroni G.J.M., Zisapel N., Cardinali D.P. Physiological effects of melatonin: role of melatonin receptors and signal transduction pathways. Prog. Neurobiol. 2008, 85:335-353.
72. Park S.Y., Jang W.J., Yi E.Y., Jang J.Y., Jung Y., Jeong J.W., Kim Y.J. Melatonin suppresses tumor angiogenesis by inhibiting HIF-1alpha stabilization under hypoxia. J. Pineal Res. 2010, 48:178-184.
73. Pévet P., Bothorel B., Slotten H., Saboureau M. The chronobiotic properties of melatonin. Cell Tissue Res. 2002, 309:183-191.
74. Pryor W., Squadrito G. The chemistry of peroxynitrite: a product from the reaction of nitric oxide with the superoxide anion. Am. J. Physiol. Lung Cell. Mol. Physiol. 1995, 268:L699-L722.
75. Ramamoorthy H., Abraham P., Isaac B. Preclinical efficacy of melatonin in the amelioration of tenofovir nephrotoxicity by the attenuation of oxidative stress, nitrosative stress, and inflammation in rats. J. Basic Clin. Physiol. Pharmacol. 2014, 1-13. 10.1515/jbcpp-2013-0135.
76. Regodón S., Ramos A., Míquez M.P., Carrillo-Vico A., Rosado J.A., Jardín I. Vaccination pre-partum enhances the beneficial effects of melatonin on the immune response and reduces platelet responsiveness in sheep. BMC Vet. Res. 2012, 8:84-86.
77. Reiter R.J. Melatonin: the chemical expression of darkness. Mol. Cell. Endocrinol. 1991, 79:C153-C158.
78. Reiter R.J. The melatonin rhythm: both a clock and a calendar. Experientia 1993, 49:654-664.
79. Reiter R.J., Melchiorri D., Sewerynek E., Poeggeler B., Barlow-Walden L., Chuang J., Ortiz G.G., Acuña-Castroviejo D. A review of the evidence supporting melatonin's role as an antioxidant. J. Pineal Res. 1995, 18:1-11.
80. Reiter R.J. Aging and oxygen toxicity: relation to changes in melatonin. Age 1997, 20:201-213.
81. Reiter R.J., Tang L., Garcia J.J., Muñoz-Hoyos A. Pharmacological actions of melatonin in oxygen radical pathophysiology. Life Sci. 1997, 60:2255-2271.
82. Reiter R.J. Melatonin: lowering the high price of free radicals. News Physiol. Sci. 2000, 15:246-250.
83. Reiter R.J., Rosales-Corral S.A., Liu X.Y., Acuña-Castroviejo D., Escames G., Tan D.X. Melatonin in the oral cavity: physiological and pathological implications. J. Periodontal Res. 2014, 10.1111/jre.12176.
84. Ressmeyer A.R., Mayo J.C., Zelosko V., Saínz R.M., Tan D.X., Poeggeler B., Antolín I., Zsizsik B.K., Reiter R.J., Handerland R. Antioxidant properties of the melatonin metabolite N1-acetyl-5-methoxykynuramine (AMK): scavenging of free radicals and prevention of protein destruction. Redox Rep. 2003, 8:205-213.
85. Ristow M., Schmeisser S. Extending life span by increasing oxidative stress. Free Radic. Biol. Med. 2011, 51:327-336.
86. Roberts J.E., Hu D.N., Wishart J.E. Pulse radiolysis studies of melatonin and 6-chloromelatonin. J. Photochem. Photobiol. 1998, 42:125-132.
87. Roth J.A., Kim B.G., Lin W.L., Cho M.I. Melatonin promotes osteoblast differentiation and bone formation. J. Biol. Chem. 1999, 274:22041-22047.
88. Sánchez-Barceló E.J., Mediavilla M.D., Tan D.X., Reiter R.J. Clinical uses of melatonin: evaluation of human trials. Curr. Med. Chem. 2010, 17:2070-2095.
89. Santello F.H., Frare E.O., dos Santos C.D., Toldo M.P., Kawasse L.M., Zucoloto S., do Prado J.C. Melatonin treatment reduces the severity of experimental Trypanosoma cruzi infection. J. Pineal Res. 2007, 42:359-363.
90. Santello F.H., Frare E.O., Caetano L.C., Alonso Toldo M.P., do Prado J.C. Melatonin enhances pro-inflammatory cytokine levels and protects against Chagas disease. J. Pineal Res. 2008, 45:79-85.
91. Schuck D.C., Ribeiro R.Y., Nery A.A., Ulrich H., García C.R. Flow cytometry as a tool for analyzing changes in Plasmodium falciparum cell cycle following treatment with indol compounds. Cytometry 2011, 79:959-964.
92. Shay D.K., Holman R.C., Roosevelt G.E., Clarke M.J., Anderson L.J. Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997. J. Infect. Dis. 2001, 183:16-22.
93. Soto-Escalona A., Finol L.T., Ryder S. Estudio de un brote de encefalitis venezolana en el distrito Páez, estado Zulia, en octubre de 1968. Invest. Clin. 1969, 10:45-47.
94. Srinivasan V., Spence D.W., Moscovitch A., Pandi-Perumal S.R., Trakht I., Brown G.M., Cardinali D.P. Malaria: therapeutic implications of melatonin. J. Pineal Res. 2010, 48:1-8.
95. Srinivasan V., Mohamed M., Zakaria R., Ahmad A.H. Malaria, anti malarial drugs and the role of melatonin. Infect. Disord. Drug Targets 2012, 12:371-379.
96. Srinivasan V., Ahmad A.H., Mohamed M., Zakaria R. Melatonin effects on Plasmodium life cycle: new avenues for therapeutic approach. Recent Pat. Endocr. Metab. Immune Drug Discov. 2012, 6:139-147.
97. Stasica P., Ulanski P., Rosiak J.M. Melatonin as a hydroxyl radical scavenger. J. Pineal Res. 1998, 26:65-66.
98. Tan D.X., Manchester L.C., Reiter R.J., Plummer B.F., Hardies L.J., Weintraub S.T., Vijayalaxmi Shepherd A.M. A novel melatonin metabolite, cyclic 3-hydroximelatonin: a biomarker of in vivo hydroxyl radical generation. Biochem. Biophys. Res. Commun. 1998, 253:614-620.
99. Tan D.X., Manchester L.C., Reiter R.J., Qi W.B., Karbownik M., Calvo J.R. Significance of melatonin in antioxidative defense system: reactions and products. Biol. Signals Recept. 2000, 9:137-159.
100. Tan D.X., Manchester L.C., Terron M.P., Flores L.J., Reiter R.J. One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species?. J. Pineal Res. 2007, 42:28-42.
101. Tan D.X., Manchester L.C., Liu X., Rosales-Corral S.A., Acuña-Castroviejo D., Reiter R.J. Mitochondria and chloroplasts as the original sites of melatonin synthesis: a hypothesis related to melatonin's primary function and evolution in eukaryotes. J. Pineal Res. 2013, 54:127-138.
102. Tapias V., Escames G., Lopez L.C., Lopez A., Camacho E., Carrion M.D., Entrena A., Gallo M.A., Espinosa A., Acuña-Castroviejo D. Melatonin and its brain metabolite N-acetyl-5-methoxykynuramine prevent mitochondrial nitric oxide synthase induction in Parkinsonian mice. J. Neurosci. Res. 2009, 87:3002-3010.
103. Taysi S., Koc M., Buyukokuroglu M.E., Altinkaynak K., Sahin Y.N. Melatonin reduces lipid peroxidation and nitric oxide during irradiation-induced oxidative injury in the rat liver. J. Pineal Res. 2003, 34:173-177.
104. Tekbas O.F., Ogur R., Korkmaz A., Kilic A., Reiter R.J. Melatonin as an antibiotic: new insights into the actions of this ubiquitous molecule. J. Pineal. Res. 2008, 44:222-226.
105. Valero N., Bonilla E., Ponds H., Chacín-Bonilla L., Añez F., Espina L.M., Medina-Leendertz S., García-Tamayo J. Melatonin induces changes to serum cytokines in mice infected with the Venezuelan equine encephalomyelitis virus. Trans. R. Soc. Trop. Med. Hyg. 2002, 96:1-4.
106. Valero N., Espina L.M., Mosquera J. Melatonin decreases nitric oxide production inducible nitric oxide synthase expression and lipid peroxidation induced by Venezuelan encephalitis equine virus in neuroblastoma cell cultures. Neurochem. Res. 2006, 31:925-932.
107. Valero N., Espina L.M., Bonilla E., Mosquera J. Melatonin decreases nitric oxide production and lipid peroxidation and increases interleukin-1 beta in the brain of mice infected by the Venezuelan equine encephalomyelitis virus. J. Pineal Res. 2007, 42:107-112.
108. Valero N., Nery A., Bonilla E., Espina L.M., Chacín-Bonilla L., Añez F., Maldonado M., Meleán E. Antagonistic effect of luzindole in mice treated with melatonin during the infection with the Venezuelan equine encephalomyelitis virus. Neurochem. Res. 2009, 34:268-273.
109. Vijayalaxmi Meltz M.L., Reiter R.J. Melatonin and protection from whole body irradiation: survival studies in mice. Mutat. Res. 1999, 425:21-27.
110. Vogel P., Abplanalp D., Kell W., Ibrahim M.S., Downs M.B., Pratt W.B., Davis K.J. Venezuelan equine encephalitis in BALB/c mice: kinetic analysis of central nervous system infection following aerosol or subcutaneous inoculation. Arch. Pathol. Lab. Med. 1996, 120:164-172.
111. Walsh J.A. Problems in recognition and diagnosis of amebiasis: estimation of the global magnitude of morbidity and mortality. Rev. Infect. Dis. 1986, 8:228-238.
112. Weaver S.C., Salas R., Rico-Hese R., Ludwig G.V., Oberste M.S., Boshell J., Tesh R.B. Re-emergence of epidemic Venezuelan equine encephalitis in South America. Lancet 1996, 348:436-440.
113. Wen L.L., Chiu C.T., Huang Y.N., Chang C.F., Wang J.Y. Rapid glia expression and release of pro-inflammatory cytokines in experimental Klebsiella pneumoniae meningoencephalitis. Exp. Neurol. 2007, 205:270-278.
114. Wickens A.P. Ageing and the free radical theory. Respir. Physiol. 2001, 128:379-391.
115. Wu K.K., Cheng H.H., Chang T.C. 5-methoxyindole metabolites of l-tryptophan: control of COX-2 expression, inflammation and tumorigenesis. J. Biomed. Sci. 2014, 21:17. 10.1186/1423-0127-21-17.
116. Wu U.I., Mai F.D., Sheu J.N., Chen L.Y., Liu Y.T., Huang H.C., Chang H.M. Melatonin inhibits microglial activation, reduces pro-inflammatory cytokine levels, and rescues hippocampal neurons of adult rats with acute Klebsiella pneumoniae meningitis. J. Pineal Res. 2011, 50:159-170.
117. Zavodnik I.B., Domansky A.V., Lapshina E.A., Bryszewska M., Reiter R.J. Melatonin directly scavenges free radicals generated in red blood cells and a cell-free system: chemiluminescence measurements and theoretical calculations. Life Sci. 2006, 79:391-400.